throbber
Traditional 510(k) Submission
`GUIDEZILA T Guide Extension Catheter
`
`K 123765 Page 1 of 2
`
`MAR 1 9 2013
`
`Submitters
`Name and
`Address
`Contact Name
`and Information
`
`Prepared
`Proprietary
`Name
`Common Name
`Product Code
`Classification
`
`Predicate
`Devices
`Device
`Description
`
`Intended Use I
`Indications for
`Use
`
`Comparison of
`Technological
`Characteristics
`
`510(k) Summary
`per 21 CIFR §807.92
`
`Boston Scientific Corporation
`One Scimed Place
`Maple Grove, MVN 55311
`Holly Ramirez
`Phone: 763-494-2113
`Fax:
`763-494-2222
`e-mail: Holly.Holmes@BSCI.com
`06 December 2012
`GUIDEZILLA Tm Guide Extension Catheter
`
`Guide Catheter
`DQY
`Class 11, 21 CFR Part 870.1250
`
`GuideLiner@®V2 Catheter
`
`K12082
`
`01 December 2011
`
`The Boston Scientific GUIDEZILLAnA Guide Extension Catheter acts as an
`extension to a traditional guide catheter. GUIDEZILLA consists of a proximal
`stainless steel hypotube with a tab used for device identification and a distal
`guide catheter segment through which interventional devices may be
`delivered. The guide catheter segment incorporates two radiopaque marker
`bands to aid in positioning the device during the procedure. A hydrophilic
`coating is ap ,plied to the distal polymer segment of the device.
`GUIDEZILLA is a 5F catheter compatible with a 6F guide catheter. The
`effective length of the device is 145 cm.
`The GUIDEZILLA Tm Guide Extension Catheter is intended to be used in
`conjunction with guide catheters to access discrete regions of the coronary
`and/or peripheral vasculature, and to facilitate placement of interventional
`devices.
`
`The GUIDEZILLA TM Guide Extension Catheter incorporates substantially
`equivalent device materials and design, packaging materials and design,
`fundamental technology, manufacturing processes, sterilization process and
`intended use as the GuideLiner® V2 (K1 12082).
`
`
`Page 1
`
`Teleflex Ex. 2200
`Medtronic v. Teleflex
`
`

`

`Traditional 510(k) Submission
`GUIDEZILLA h Guide Extension Catheter
`
`K 123765 Page 2 of 2
`
`Performance
`Data
`
`Bench testing and bioconipatibility testing were performed to support a
`determination of substantial equivalence. The results of these tests provide
`reasonable assurance that the proposed device has been designed and
`tested to assure conformance to the requirements for its intended use. No
`new safety or performance issues were raised during the testing.
`The following biocompatibility tests were completed on the GUIDEZILLA h
`Guide Extension Catheter:
`Cytotoxicity
`Sensitization
`Intracutaneous Reactivity
`Acute Systemic Toxicity
`Materials Mediated Pyrogenicity
`USP Physicochemnical
`
`Direct Contact Hemolysis
`Hemolysis Extract
`Complement Activation
`Partial Thromboplastin Time
`In Vitro Hemocompatibility
`Latex
`
`The following in-vitro performance tests were completed of the GUIDEZILLA TM
`Guide Extension Catheter:
`Effective Length
`Outer Diameter
`Inner Diameter
`Full Unit Tensile
`Kink Resistance
`Tip Deflection
`Torque Strength
`
`Radiopacity
`Dye Flow
`Coating Integrity
`Particulate Evaluation
`Corrosion Resistance
`Device Compatibility
`Packaging Integrity
`
`Clinical Testing
`
`Clinical Evaluation was not required for these devices.
`
`Conclusion
`
`Based on the indications for use, technological characteristics, and safety and
`performance testing, the GUIDEZILLA Tm Guide Extension Catheter has been
`shown to be appropriate for its intended use and is considered to be
`substantially equivalent to the GuideLiner® V2 (K1 12082).
`
`
`Page 2
`
`Teleflex Ex. 2200
`Medtronic v. Teleflex
`
`

`

`DEPARTMENT OF HEALTH & HUMAN SERVICES
`
`Public Health Service
`
`March 19, 2013
`
`Food and Drug Administration
`10903 New Hampshire Avenue
`Document Control Center - W066-6609
`Silver Spring, MD 20993-0002
`
`Boston Scientific Corporation
`C/O Holly Ramirez
`One Scimed Place
`Maple Grove, MIN 55311
`
`Re: K123765
`Trade/Device Name: GuidezillaTM Guide Extension Catheter
`Regulation Number: 21 CFR 870.1250
`Regulation Name: Percutaneous Catheter
`Regulatory Class: Class 1I
`Product Code: DQY
`Dated: February 15, 2013
`Received: February 19, 2013
`
`Dear Ms. Ramirez:
`
`We have reviewed your Section 5 1 0(k) premarket notification of intent to market the device
`referenced above and have determined the device is substantially equivalent (for the indications
`for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
`commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
`devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
`and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
`You may, therefore, market the device, subject to the general controls provisions of the Act.
`The general controls provisions of the Act include requirements for annual registration, listing of
`devices, good manufacturing practice, labeling, and prohibitions against misbranding and
`adulteration. Please note: CDRH does not evaluate information related to contract liability
`warranties. We remind you; however, that device labeling must be truthful and not misleading.
`
`If your device is classified (see above) into either class 11 (Special Controls) or class III (PMA), it
`may be subject to additional controls. Existing major regulations affecting your device can be
`found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
`publish further announcements concerning your device in the Federal Register.
`
`Please be advised that FDA's issuance of a substantial equivalence determination does not mean
`that FDA has made a determination that your device complies with other requirements of the Act
`or any Federal statutes and regulations administered by other Federal agencies. You must
`comply with all the Act's requirements, including, but not limited to: registration and listing (21
`CFI{ Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical
`device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
`forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
`product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
`
`
`Page 3
`
`Teleflex Ex. 2200
`Medtronic v. Teleflex
`
`

`

`Page 2 - Ms. Holly Ramirez
`
`If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
`go to http://.wwv.fda. 20v/AboutFDA/CentersOffices/CDRH/CDRHOffiCes/ucm 115809.htm for
`the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please
`note the regulation entitled, "Misbranding by reference to premarket notification" (2 1 CFR Part
`807.97). For questions regarding the reporting of adverse events under the MDR regulation (21
`CFR Part 803), please go to
`http://www.fda.gov/MedicalDevices/Safety/ReyortaProblem/default.htm
`of Surveillance and Biometrics/Division of Postmarket Surveillance.
`
`for the CDRH's Office
`
`You may obtain other general information on your responsibilities under the Act from the
`Division of Small Manufacturers, International and Consumer Assistance at its toll-free number
`(800) 63 8-2041 or (301) 796-7100 or at its Internet address
`http://vw-v.fda.gov/MedicalDevices/ResourcesforYou/Industrv/default.htm.
`
`Sincerely yours,
`
`iilbrenner
`Matthew
`for Brain Zuckerman, M.D.
`Director, Division of Cardiovascular Devices
`Office of Device Evaluation
`Center for Devices and
`Radiological Health
`
`Enclosure
`
`
`Page 4
`
`Teleflex Ex. 2200
`Medtronic v. Teleflex
`
`

`

`Indications for Use
`
`510(k) Number (if known): K123765
`
`Device Name:
`
`GUIDEZILLATM Guide Extension Catheter
`
`Indications for Use:
`The Guidezilla guide extension catheter is intended to be used in conjunction with guide
`catheters to access discrete regions of the coronary and/or peripheral vasculature, and
`to facilitate placement of interventional devices.
`
`Prescription Use __ANX/OR
`(Part 21 CFR 801 Subpart D)
`
`ANIR(21
`
`Over-The-Counter Use ___
`CFR 801 Subpart C)
`
`(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER
`PAGE IF NEEDED)
`
`Concurrence of CDRH, Office of Device Evaluation (ODE)
`
`Matthew QI-Tiiiebrenner
`
`Boston Scientific Corporation
`
`Page 1 of 1
`
`
`Page 5
`
`Teleflex Ex. 2200
`Medtronic v. Teleflex
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket